– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue –
Barchart Research What to Expect from PTCT Earnings PTCT Generated July 29, 2026 Current Price $74.49 EPS Estimate $$-0.16 Consensus Rating Moderate Buy Average Move 7.47% Can PTC Therapeutics Finally...
CONSHOHOCKEN, Pa. , July 23, 2026 /PRNewswire/ -- Leading private markets investment management firm Hamilton Lane (Nasdaq: HLNE) announced that its Board of Directors elected Michael Schmertzler...
WARREN, N.J. , July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial...
WARREN, N.J. , June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate...
– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity –
– Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity –
PTC Therapeutics (NASDAQ:PTCT) reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or PKU.Chief...